Funding for this research was provided by:
National Institutes of Health (5R21NS093993-02)
Text and Data Mining valid from 2019-08-16
Received: 29 October 2018
Accepted: 8 August 2019
First Online: 16 August 2019
: The housing of the animals and all procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (U.S. National Institutes of Health) and were approved by the Van Andel Research Institute’s IACUC (AUP 16–01-003). This article does not contain any studies with human participants performed by any of the authors.
: P.B. has received commercial support as a consultant from Renovo Neural, Inc., Roche, and Teva Inc., Lundbeck A/S, AbbVie, Neuroderm, Cellular Dynamics International, ClearView Healthcare, FCB Health, IOS Press Partners and Capital Technologies, Inc. P.B. has received commercial support for grants/research from Renovo and Teva/Lundbeck. P.B. has ownership interests in Acousort AB and is on the steering committee of the NILO-PD trial. The authors declare no additional competing financial interests.